| Literature DB >> 33152703 |
Steven M Horwitz1, Stephen Ansell2, Weiyun Z Ai3, Jeffrey Barnes4, Stefan K Barta5, Mark W Clemens6, Ahmet Dogan1, Aaron M Goodman7, Gaurav Goyal8, Joan Guitart9, Ahmad Halwani10, Bradley M Haverkos11, Richard T Hoppe12, Eric Jacobsen13, Deepa Jagadeesh14, Allison Jones15, Youn H Kim12, Neha Mehta-Shah16, Elise A Olsen17, Barbara Pro9, Saurabh A Rajguru18, Sima Rozati19, Jonathan Said20, Aaron Shaver21, Andrei Shustov22, Lubomir Sokol23, Pallawi Torka24, Carlos Torres-Cabala6, Ryan Wilcox25, Basem M William26, Jasmine Zain27, Mary A Dwyer28, Hema Sundar28.
Abstract
Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.Entities:
Year: 2020 PMID： 33152703 DOI： 10.6004/jnccn.2020.0053
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908